fexofenadine (OTC)Brand and Other Names:Allegra, Allegra Allergy 12 Hour, more...Allegra Allergy 24 Hour, Children's Allegra Allergy, Mucinex Allergy

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablets

  • 30mg
  • 60mg
  • 180mg

oral suspension

  • 30mg/5mL

oral disintegrating tablets

  • 30mg
more...

Seasonal Allergic Rhinitis/Chronic Idiopathic Urticaria

180 mg PO qDay or 60 mg PO BID

Dosing Modifications

Renal impairment (CrCl <80 mL/min): 60 mg PO qDay initially

Administration

Allegra ODT: Allow to disintegrate on tongue, followed by swallowing with or without water; take on empty stomach; do not chew

Coadministration with grapefruit, apple, or orange juice reduces bioavailability of fexofenadine by inhibiting P-gp; separate administration by at least 4 hr

Dosage Forms & Strengths

tablets

  • 30mg
  • 60mg
  • 180mg

oral suspension

  • 30mg/5mL

oral disintegrating tablets

  • 30mg
more...

Seasonal Allergic Rhinitis

<2 years: Use not recommended

2-12 years: 30 mg PO BID

>12 years: 60 mg PO BID OR 180 mg PO qDay

Allegra ODT

  • 6-12 years: 30 mg PO BID

Chronic Idiopathic Urticaria

<6 months: Use not recommended

6 months-2 years: 15 mg PO BID

2-12 years: 30 mg PO BID

>12 years: 60 mg PO BID OR 180 mg PO qDay

Allegra ODT

  • 6-12 years: 30 mg PO BID

Dosing Modifications

Renal impairment (CrCl <80mL/min)

  • <6 months: Safety and efficacy not established
  • 6 months to 2 years: 15 mg PO qDay, initially
  • 2-12 years: 30 mg PO qDay, initially
  • >12 years: 60 mg PO qDay, initially

Administration

Allegra ODT: Allow to disintegrate on tongue, followed by swallowing with or without water; take on empty stomach; do not chew

Coadministration with grapefruit, apple, or orange juice reduces bioavailability of fexofenadine by inhibiting P-gp; separate administration by at least 4 hr

Next

Interactions

Interaction Checker

fexofenadine and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            Varies in incidence and severity with the individual drug; also, individual patients vary in susceptibility

            >10%

            Vomiting (6-12%)

            1-10%

            Headache (5-10%)

            Cough (4%)

            Diarrhea (3-4%)

            URTI (3%)

            Back pain (2-3%)

            Pyrexia (2%)

            Dysmenorrhea (2%)

            Dizziness (2%)

            Stomach discomfort (2%)

            Pain in extremity (2%)

            Somnolence (1-3%)

            Rhinorrhea (1-2%)

            Postmarketing Reports

            Sleep disorders (insomnia, paranoia)

            Nervousness

            Hypersensitivity reactions (anaphylaxis, urticaria, angioedema, chest tightness, dyspnea, flushing, pruritus, rash)

            Previous
            Next

            Warnings

            Contraindications

            Hypersensitivity

            Cautions

            Allegra ODT contains phenylalanine

            Severe renal impairment

            Coadministration with fruit juice may decrease efficacy

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy category: C

            Lactation: Excretion in milk unknown; use with caution (AAP states “compatible with nursing”)

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            H1 histamine receptor antagonist; competes for H1-receptor sites in target cells in the respiratory tract, blood vessels, and gastrointestinal tract; major metabolite of terfenadine

            Absorption

            Duration: ≥12 hr

            Peak serum time: 2-3 hr (tablet); 2 hr (ODT); 1 hr (suspension)

            Peak plasma concentration: 131 ng/mL

            Distribution

            Protein bound: 60-70%

            Metabolism

            Hepatic (5%)

            Elimination

            Half-life: 14.4 hr (31-72% longer in renal impairment)

            Excretion: Feces (80%), urine (11%)

            Previous
            Next

            Images

            Previous
            Next
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.